Therapeutic Immunization against Glioblastoma

about

Therapeutic Immunization against Glioblastoma

Item

http://www.wikidata.org/entity/Q58700123

description

im August 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2018

@uk

name

Therapeutic Immunization against Glioblastoma

@en

Therapeutic Immunization against Glioblastoma

@nl

type

Item

label

Therapeutic Immunization against Glioblastoma

@en

Therapeutic Immunization against Glioblastoma

@nl

prefLabel

Therapeutic Immunization against Glioblastoma

@en

Therapeutic Immunization against Glioblastoma

@nl

P1476

Therapeutic Immunization against Glioblastoma

@en

P2093

Anna M Strik

http://www.w3.org/2001/XMLSchema#string

Beverly D Fu

http://www.w3.org/2001/XMLSchema#string

Chrystel Pretto

http://www.w3.org/2001/XMLSchema#string

Daniela A Bota

http://www.w3.org/2001/XMLSchema#string

Denis Pierre

http://www.w3.org/2001/XMLSchema#string

Florence M Hofman

http://www.w3.org/2001/XMLSchema#string

Frank P K Hsu

http://www.w3.org/2001/XMLSchema#string

Jinah Chung

http://www.w3.org/2001/XMLSchema#string

Jose A Carrillo

http://www.w3.org/2001/XMLSchema#string

Laurent Deviller

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution

P2860

A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma

An Overview of Alternating Electric Fields Therapy (NovoTTF Therapy) for the Treatment of Malignant Glioma

Bevacizumab for glioblastoma

Nonsurgical treatment of recurrent glioblastoma

A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.

Scale to predict survival after surgery for recurrent glioblastoma multiforme

P304

2540

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.3390/IJMS19092540

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Apostolos Stathopoulos

Raphael Zidovetzki

P5008

ScienceSource

P577

2018-08-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30150597

http://www.w3.org/2001/XMLSchema#string

P921

brain cancer

brain neoplasm

glioblastoma

preventive health services

biomedical investigative technique

molecular biology

catalysis

P932

6163986

http://www.w3.org/2001/XMLSchema#string